Document Detail


Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
MedLine Citation:
PMID:  16697316     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs).
BACKGROUND: Atrial fibrillation is associated with an increased risk of adverse CV outcomes in patients with CHF and reduced EF. The risk of AF in patients with CHF and preserved left ventricular ejection fraction (PEF) is unknown.
METHODS: A total of 7,599 patients with symptomatic CHF were randomized to candesartan or placebo. Patients were divided by baseline EF (< or =40% or >40%) in low or preserved EF groups. Major outcomes were cardiovascular death or hospitalization for worsening heart failure, and all-cause mortality. Median follow-up was 37.7 months.
RESULTS: A total of 670 (17%) patients in the low EF group and 478 (19%) in the PEF group had AF at baseline. Atrial fibrillation predicted a high risk of cardiovascular morbidity and mortality regardless of baseline EF. Patients with AF and low EF had the highest absolute risk for adverse CV outcomes. However, AF was associated with greater relative increased risk of the major outcomes in patients with PEF than in patients with low EF: hazard ratio 1.72 (95% confidence interval [CI] 1.45 to 2.06) versus 1.29 (95% CI 1.14 to 1.46), respectively. The same was true for the risk of all-cause mortality. Candesartan was associated with similar treatment effects regardless of baseline rhythm.
CONCLUSIONS: Atrial fibrillation is associated with an increased risk of CV outcomes in patients with CHF and either reduced EF or PEF. Candesartan improved outcomes similarly regardless of baseline rhythm.
Authors:
Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer;
Related Documents :
19340356 - Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibri...
11157596 - Long-term prognostic value of dobutamine stress echocardiography in patients with atria...
17100676 - Slow pathway ablation decreases vulnerability to pacing-induced atrial fibrillation: po...
20693576 - Clinical characteristics of patients with persistent atrial fibrillation successfully t...
10392396 - Possible involvement of hypothyroidism as a cause of lithium-induced sinus node dysfunc...
23794296 - Ineffective esophageal motility and gastroesophageal reflux disease: a close relationship?
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-04-27
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  47     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-15     Completed Date:  2006-05-25     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1997-2004     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Atrial Fibrillation / complications,  drug therapy*,  mortality*
Benzimidazoles / therapeutic use
Cardiovascular Diseases / mortality
Chronic Disease
Female
Heart Failure / complications,  drug therapy*,  mortality*
Hospitalization
Humans
Male
Middle Aged
Prognosis
Risk
Stroke Volume
Tetrazoles / therapeutic use
Ventricular Dysfunction, Left / etiology
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Tetrazoles; S8Q36MD2XX/candesartan
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2007 Jan 23;49(3):376; author reply 376-7   [PMID:  17239723 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Renal impairment and outcomes in heart failure: systematic review and meta-analysis.
Next Document:  Sites of focal atrial activity characterized by endocardial mapping during atrial fibrillation.